SAN ANTONIO--(BUSINESS WIRE)--Aug 12, 2013--Kinetic Concepts, Inc. today announced the global launch of the new V.A.C. VeraFlo? Large Dressing for easy application of V.A.C. VeraFlo? Instillation Therapy on larger wounds and wounds requiring additional dressing customization. The introduction of the V.A.C. VeraFlo? Large Dressing complements the V.A.C. VeraFlo? Dressing product line and means clinicians can choose from a complete portfolio of instillation dressings to treat wounds of various sizes and complexities.
"Clinicians tell us they are experiencing the 'wow' effect when using V.A.C. VeraFlo? Therapy on their patients," said Ron Silverman, MD, Chief Medical Officer, KCI. "The launch of the new large dressing means it becomes even easier to apply instillation therapy to different types of wounds."
KCI recently demonstrated its commitment and investment in the future of V.A.C. VeraFlo? Therapy as a better treatment option for customers and patients by announcing the initiation of patient enrollment in a multi-center clinical study assessing the benefits of negative pressure wound therapy (NPWT) with intermittent instillation therapy using a topical wound cleanser.
This study follows an independent retrospective, historical cohort-controlled study recently presented at the 2013 Technology Innovations in Plastic Surgery meeting in San Francisco, California by physicians from MedStar Georgetown University Hospital, Center for Wound Healing, led by Christopher E. Attinger, M.D., Chief, Division of Wound Healing 1.
The results, involving 142 patients, demonstrated the effectiveness of V.A.C. VeraFlo? Therapy with instillation with Prontosan R Wound Irrigation Solution compared to V.A.C. R Therapy in the adjunctive treatment of wounds that required hospital admission and serial surgical debridement. The results of this study suggested a significant decrease in operating room visits for study patients who received V.A.C. VeraFlo? Therapy with Prontosan R Wound Irrigation Solution instillation. Further, the investigators reported a trend toward a two- to three-day reduction in hospital stay compared to traditional V.A.C. R Therapy in these patients.
This growing body of evidence, combined with the launch of the V.A.C. VeraFlo? Large Dressing, contributes to better treatment options for customers and patients.
For more information about KCI and V.A.C. VeraFlo? Therapy using the V.A.C.Ulta? Negative Pressure Wound Therapy System, please visit www.KCI1.com.
Prontosan is a trademark of B.Braun Medical, Inc.
1. Powers KA, Kim PJ, Attinger CE, et al. Early Experience with Negative Pressure Wound Therapy with Instillation in Acutely Infected Wounds. Presented at the 2013 Technology Innovations in Plastic Surgery Conference, May 31-June 2, 2013, San Francisco, CA.
KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively affecting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C. R Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at? www.KCI1.com.
CONTACT: KCI Corporate Communications
Mike Barger, +1-210-255-6824
KEYWORD: UNITED STATES EUROPE ASIA PACIFIC NORTH AMERICA TEXAS
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY MEDICAL DEVICES MEDICAL SUPPLIES
SOURCE: Kinetic Concepts, Inc.
Copyright Business Wire 2013
PUB: 08/12/2013 10:00 AM/DISC: 08/12/2013 10:00 AM